CompletedPhase 3NCT02688140

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Studying Acute promyelocytic leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Technische Universität Dresden
Principal Investigator: Uwe Platzbecker, Prof. Dr.
Technische Universität Dresden (TUD)
Intervention: Arsenic trioxide(drug)
Enrollment: 135 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2016 – 2025

Study locations (8)

French-Belgian-Swiss APL study group, Multiple Locations, France
AML-CG study group, Multiple Locations, Germany
AML-SG study group, Multiple Locations, Germany
OSHO study group, Multiple Locations, Germany
SAL study group, Multiple Locations, Germany
GIMEMA study group, Multiple Locations, Italy
HOVON study group, Multiple Locations, Netherlands
PETHEMA study group, Multiple Locations, Spain

Collaborators

Gruppo Italiano Malattie EMatologiche dell'Adulto · Groupe Francophone des Myelodysplasies · HOVON - Dutch Haemato-Oncology Association · Programa para el Tratamiento de Hemopatías Malignas · German Federal Ministry of Education and Research · Teva Pharmaceuticals Europe

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02688140 on ClinicalTrials.gov

Other trials for Acute promyelocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute promyelocytic leukemia →

← Back to all trials